nach oben

Die Innere Medizin

Erschienen in:

01.05.2008 | Schwerpunkt: Hormontherapie

Hormontherapie und Anti-Aging

Gibt es eine Indikation?

verfasst von: D. Heutling, Prof. Dr. H. Lehnert, MD FRCP

Erschienen in: Die Innere Medizin | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Wunsch nach einem langen Leben ist tief in den meisten Menschen verwurzelt. Erfreulicherweise hat die Lebenserwartung in den letzten Jahrzehnten deutlich zugenommen. Auf der anderen Seite aber ist ein fortgeschrittenes Alter mit einer Zunahme der Morbidität verbunden. Daher ist es notwendig, Strategien zu entwickeln, die über eine alleinige Lebensverlängerung hinausgehend zu einer Anhebung der Lebensqualität im Alter führen. Verschiedene Substanzen, welche Alterungsprozesse bremsen sowie Krebs- und degenerativen Erkrankungen vorbeugen sollen, sind Gegenstand wissenschaftlicher Untersuchungen. Insbesondere Hormonen wird eine Anti-Aging-Wirkung zugeschrieben. Diese Übersicht stellt die hierzu vorliegenden Studiendaten vor.

Abdu TA, Neary R, Elhadd TA et al. (2001) Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 55: 209–216

Anisimov VN, Zavarzina NY, Zabezhinski MA et al. (2001) Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol A Biol Sci Med Sci 56: B311–B323PubMed

Arlt W, Callies F, Koehler I et al. (2001) Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 86: 4686–4692PubMedCrossRef

Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169–1172PubMedCrossRef

Baulieu EE, Thomas G, Legrain S et al. (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 97: 4279–4284PubMedCrossRef

Bengtsson BA, Koppeschaar HP, Abs R et al. (1999) Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. J Clin Endocrinol Metab 84: 4291–4292PubMedCrossRef

Blask DE, Dauchy RT, Sauer LA (2005) Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27: 179–188PubMedCrossRef

Cohn L, Feller AG, Draper MW et al. (1993) Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 39: 417–425

Dean CE (2000) Prasterone (DHEA) and mania. Ann Pharmacother 34: 1419–1422PubMed

10.

Elhadd TA, Abdu TA, Clayton R (2001) Hypopituitarism and atherosclerosis. Ann Med 33: 477–485PubMedCrossRef

11.

Feldman HA, Goldstein I, Hatzichristou DG et al. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54–61PubMed

12.

Ferrari E, Cravello L, Falvo F et al. (2008) Neuroendocrine features in extreme longevity. Exp Gerontol 43: 88–94PubMedCrossRef

13.

Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL et al. (1999) Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 84: 1527–1533PubMedCrossRef

14.

Hankinson SE (2005) Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 24: 3–15PubMed

15.

Hennessey JV, Chromiak JA, DellaVentura S et al. (2001) Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 49: 852–858PubMedCrossRef

16.

Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2: CD001520PubMed

17.

Heutling D, Lehnert H (2005) Hormone therapy and menopause. Dtsch Med Wochenschr 130: 829–834PubMedCrossRef

18.

Huppert FA, Van Niekerk JK (2001) Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev 4: CD000304

19.

Iranmanesh A, Lizarralde G, Veldhuis JD (1991) Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 73: 1081–1088PubMed

20.

Iwasaki Y, Asai M, Yoshida M et al. (2004) Dehydroepiandrosterone-sulfate inhibits nuclear factor-kappaB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab 89: 3449–3454PubMedCrossRef

21.

Jankowski CM, Gozansky WS, Schwartz RS et al. (2006) Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91: 2986–2993PubMedCrossRef

22.

Jenkins PJ (2006) Cancers associated with acromegaly. Neuroendocrinology 83: 218–223PubMedCrossRef

23.

Johansson T, Le GP (2005) The effect of dehydroepiandrosterone sulfate and allopregnanolone sulfate on the binding of [(3)H]ifenprodil to the N-methyl-d-aspartate receptor in rat frontal cortex membrane. J Steroid Biochem Mol Biol 94: 263–266PubMedCrossRef

24.

Kawano H, Yasue H, Kitagawa A et al. (2003) Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88: 3190–3195PubMedCrossRef

25.

Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, Forsling ML (1998) Melatonin administration and pituitary hormone secretion. Clin Endocrinol (Oxf) 48: 31–37

26.

Kroboth PD, Salek FS, Pittenger AL et al. (1999) DHEA and DHEA-S: a review. J Clin Pharmacol 39: 327–348PubMedCrossRef

27.

Labrie F, Diamond P, Cusan L et al. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82: 3498–3505PubMedCrossRef

28.

Labrie F, Luu-The V, Labrie C, Simard J (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22: 185–212PubMedCrossRef

29.

Legrain S, Massien C, Lahlou N et al. (2000) Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. Clin Endocrinol Metab 85: 3208–3217CrossRef

30.

Lemus-Wilson A, Kelly PA, Blask DE (1995) Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer 72: 1435–1440PubMed

31.

Leonsson M, Hulthe J, Oscarsson J et al. (2002) Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf) 57: 751–759

32.

Li L, Yu H, Schumacher F et al. (2003) Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14: 721–726PubMedCrossRef

33.

Liu D, Dillon JS (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277: 21379–21388PubMedCrossRef

34.

Markowitz JS, Carson WH, Jackson CW (1999) Possible dihydroepiandrosterone-induced mania. Biol Psychiatry 45: 241–242PubMedCrossRef

35.

Mattison JA, Lane MA, Roth GS, Ingram DK (2003) Calorie restriction in rhesus monkeys. Exp Gerontol 38: 35–46PubMedCrossRef

36.

Morales AJ, Haubrich RH, Hwang JY et al. (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 49: 421–432

37.

Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78: 1360–1367PubMedCrossRef

38.

Nair KS, Rizza RA, O’Brien P et al. (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647–1659PubMedCrossRef

39.

Orentreich N, Brind JL, Rizer RL, Vogelman JH (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59: 551–555PubMed

40.

Orentreich N, Brind JL, Vogelman JH et al. (1992) Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75: 1002–1004PubMedCrossRef

41.

Papadakis MA, Grady D, Black D et al. (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124: 708–716PubMed

42.

Paparrigopoulos T (2002) Melatonin response to atenolol administration in depression: indication of beta-adrenoceptor dysfunction in a subtype of depression. Acta Psychiatr Scand 106: 440–445PubMedCrossRef

43.

Percheron G, Hogrel JY, Denot-Ledunois S et al. (2003) Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 163: 720–727PubMedCrossRef

44.

Reiter WJ, Pycha A, Schatzl G et al. (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53: 590–594PubMedCrossRef

45.

Reiter WJ, Schatzl G, Mark I et al. (2001) Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 29: 278–281PubMedCrossRef

46.

Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285–288PubMedCrossRef

47.

Roth GS, Lane MA, Ingram DK et al. (2002) Biomarkers of caloric restriction may predict longevity in humans. Science 297: 811PubMedCrossRef

48.

Roth GS, Lesnikov V, Lesnikov M et al. (2001) Dietary caloric restriction prevents the age-related decline in plasma melatonin levels of rhesus monkeys. J Clin Endocrinol Metab 86: 3292–3295PubMedCrossRef

49.

Rudman D, Feller AG, Nagraj HS et al. (1990) Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1–6PubMed

50.

Sauer LA, Dauchy RT, Blask DE (2001) Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction. Life Sci 68: 2835–2844PubMedCrossRef

51.

Schwartz AG, Pashko LL (2004) Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 3: 171–187PubMedCrossRef

52.

Shi R, Yu H, McLarty J, Glass J (2004) IGF-I and breast cancer: a meta-analysis. Int J Cancer 111: 418–423PubMedCrossRef

53.

Sonntag WE, Carter CS, Ikeno Y et al. (2005) Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 146: 2920–2932PubMedCrossRef

54.

Sousa A, Ticku MK (1997) Interactions of the neurosteroid dehydroepiandrosterone sulfate with the GABA(A) receptor complex reveals that it may act via the picrotoxin site. J Pharmacol Exp Ther 282: 827–833PubMed

55.

Srinivasan V, Pandi-Perumal SR, Maestroni GJ et al. (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res 7: 293–318PubMedCrossRef

56.

Svensson J, Bengtsson BA, Rosen T et al. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89: 3306–3312PubMedCrossRef

57.

Taaffe DR, Jin IH, Vu TH et al. (1996) Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 81: 421–425PubMedCrossRef

58.

Taaffe DR, Lewis B, Marcus R (1994) Quantifying the effect of hand preference on upper limb bone mineral and soft tissue composition in young and elderly women by dual-energy X-ray absorptiometry. Clin Physiol 14: 393–404PubMedCrossRef

59.

Takebayashi M, Hayashi T, Su TP (2004) A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 37 (Suppl 3): S208–S213PubMedCrossRef

60.

Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J (2002) A case report of mania precipitated by use of DHEA. Encephale 28: 563–566PubMed

61.

Vesnushkin GM, Plotnikova NA, Semenchenko AI, Anisimov VN (2006) Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. J Exp Clin Cancer Res 25: 507–513PubMed

62.

Villareal DT, Holloszy JO (2004) Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292: 2243–2248PubMedCrossRef

63.

Villareal DT, Holloszy JO (2006) DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. Am J Physiol Endocrinol Metab 291: E1003–E1008PubMedCrossRef

64.

Wallace JD, Cuneo RC, Baxter R et al. (1999) Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab 84: 3591–3601PubMedCrossRef

65.

Wetterberg L, Bergiannaki JD, Paparrigopoulos T et al. (1999) Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 24: 209–226PubMedCrossRef

66.

Wilson ST, Blask DE, Lemus-Wilson AM (1992) Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab 75: 669–670PubMedCrossRef

67.

Wolkowitz OM, Kramer JH, Reus VI et al. (2003) DHEA treatment of Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. Neurology 60: 1071–1076PubMed

68.

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472–1489PubMedCrossRef

Titel: Hormontherapie und Anti-Aging
Gibt es eine Indikation?
verfasst von: D. Heutling
Prof. Dr. H. Lehnert, MD FRCP
Publikationsdatum: 01.05.2008
Verlag: Springer-Verlag
Erschienen in: Die Innere Medizin / Ausgabe 5/2008
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-008-2110-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Mitteilungen der DGIM 05/08

Hormontherapie

Diverse

Substitution mit Nebennierensteroiden

Die Therapie des Hypogonadismus des Mannes